L'Oreal S.A. header image

L'Oreal S.A.

OR

Equity

ISIN FR0000120321 / Valor 502805

Euronext - Euronext Paris (2025-11-21)
EUR 361.50+2.66%

L'Oreal S.A.
UMushroom community rating:

star star star star star
4.00 2 votes No rating yet
NegativeNeutralPositive

About company

L'Oreal S.A. is a global cosmetics company with a unique organizational structure that combines strategic concentration with operational decentralization. The company empowers local teams to ensure that they are close and relevant to consumers in every country, creating and producing cosmetics at a local level to meet the specific needs of each market. L'Oreal has a worldwide network of Research & Innovation and marketing hubs in key strategic markets, supported by a global industrial presence to bring innovations to market efficiently. The company's success is driven by its global R&I, diverse portfolio of brands, and integrated industrial production, along with corporate functions such as Administration & Finance, Digital, HR, Communications, and Corporate Responsibility.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (20.10.2025):

L'Oréal S.A. reported solid financial results for the first quarter of 2025, achieving reported sales growth of 4.4% to €11.73 billion and like-for-like growth of 3.5%. The company outperformed the global beauty market, with all divisions experiencing growth and strong performance in emerging markets and Europe.

Sales Growth

In the first quarter of 2025, L'Oréal S.A. achieved reported sales of €11.73 billion, reflecting a 4.4% increase and a like-for-like growth of 3.5%. This growth was supported by a positive net impact of €100 million from the 2024 and 2025 IT transformation phases.

Division Performance

All divisions saw sales growth, with L’Oréal Luxe leading at a 7.3% reported increase. Professional Products grew by 2.7%, Consumer Products by 2.5%, and Dermatological Beauty by 3.5%. Fragrances and haircare remained the fastest-growing categories across divisions.

Regional Performance

Sales growth was strongest in emerging markets, particularly in SAPMENA-SSA, and Europe continued to deliver robust growth with a reported increase of 4.9%. North America faced challenges with a reported decline of 1.4%, while North Asia saw an 8.4% growth.

Awards and Recognition

L'Oréal S.A. was awarded a CDP triple ‘A’ score for the ninth consecutive year and was recognized as one of the World’s Most Ethical Companies by Ethisphere for the 16th time, highlighting the company's commitment to sustainability and ethical practices.

CEO Commentary

Nicolas Hieronimus, CEO of L'Oréal, expressed confidence in the company's ability to continue outperforming the global beauty market despite economic and geopolitical challenges. He highlighted the positive impact of the “Beauty Stimulus” Plan and emphasized the focus on driving growth and managing profitability.

Summarized from source with an LLMView Source

Key figures

12.0%1Y
3.80%3Y
15.8%5Y

Performance

24.9%1Y
22.7%3Y
23.6%5Y

Volatility

Market cap

222426 M

Market cap (USD)

Daily traded volume (Shares)

361,045

Daily traded volume (Shares)

1 day high/low

343.5 / 337.1

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

2 votes
Performance:
starstarstarstarstar
4.50
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
4.50
Nature:
starstarstarstarstar
3.50
Nargita Apte
United Kingdom, 20 Oct 2025
star star star star star
Recent Press Release - they are acquiring Kering's beauty portfolio so likely to rise
Federico Ferrari
Switzerland, 19 Oct 2025
star star star star star
L’Oréal is a strong stock to invest in. In 2023, it reported over €38 billion in revenue. The company operates in more than 150 countries. It consistently pays dividends to investors. Stable and solid, it inspires trust on the stock market.

EQUITIES OF THE SAME SECTOR

Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.94%EUR 1.05
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.62%USD 101.12
Dr Reddy'S Laboratories Ltd
Dr Reddy'S Laboratories Ltd Dr Reddy'S Laboratories Ltd Valor: 1221723
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 13.91
COSMO Pharmaceuticals N.V.
COSMO Pharmaceuticals N.V. COSMO Pharmaceuticals N.V. Valor: 32590356
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.45%CHF 67.10
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03
Essity AB
Essity AB Essity AB Valor: 36851944
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%SEK 260.90